P3A Forum
Psilocybine en fin de vie
Audace, Acceptabilité, Accès
March 22nd, 2024 – Clarendon Hotel, Quebec
Objectives
- Provide an overview of the professional, social, legal, ethical, and economic issues related to accessing psilocybin-assisted therapy for relieving existential distress in individuals facing a serious and incurable illness in Quebec.
- Bring together various actors involved in palliative and end-of-life care in Quebec to co-create recommendations that establish guidelines for the therapeutic use of psilocybin within the Quebec medical-legal context.
- Contribute to the discussion regarding one of the recommendations of the Special Joint Committee on Medical Assistance in Dying in Canada, which states that “Health Canada should review relevant regulations to improve access to promising therapies, such as psilocybin, in the context of palliative care.
- Ultimately, contribute to improving the quality of care for individuals facing a serious and incurable illness in Quebec.
Target audience: This invitation-only Forum is aimed at decision-makers, healthcare professionals, patients, citizens, and legislators representing organizations involved in palliative and end-of-life care.
Preliminary schedule for March 22nd:
8:00 am: Welcome and Opening Remarks
8:15 am. to 8:45 am : Existential distress in palliative care
Dr Annie Tremblay, CHU de Québec-Université Laval
8:45 am. to 9:15 am: Psychedelic therapies: Foundations and practices
Dr Houman Farzin, Jewish General Hospital, McGill University
9:15 am to 10:15 am: Ethical, legal, and economic issues of psilocybin-assisted therapy in palliative care
Me Nicholas Pope, Hameed Law
Pr Yann Joly, McGill University
Me Pierre Deschamps, Commission sur les soins de fin de vie
10:30 am to 11:00 am : Social and professional acceptability of psilocybin-assisted therapy
Louis Plourde, Ph. D. student, Faculty of Pharmacy, Université Laval
Marianne Masse-Grenier, master’s student, Faculty of Pharmacy, Université Laval
11:00 am to 11:30 am: Equity in psilocybin-assisted therapy in palliative care
Dr Justin Sanders, McGill University
11:30 am to 12:00 pm: Testimonials from people who have had access to therapy
Madam FM & Mister RF
1:15 pm to 2:15 pm : Round Table: Quebec Experiences and Perspectives
Physicians, patients, managers
2:15 pm to 3:00 pm : Workshops
3:15 pm to 4:45 pm : Discussions and Deliberations
4:45 pm : Conclusions and Closing Remarks
P3A Forum partners
Visionary partners
Associated partners
Collaborative partners
Partnership opportunities
The ‘Partners’ of the P3A Forum will be recognized as part of this event.
See how you can contribute:
The P3A Forum « Psilocybine en fin de vie Audace, Acceptabilité, Accès » is made possible through the
financial support of the Fonds de recherche du Québec.
